title: Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD).
authors.forename: A M
authors.initials: AM
authors.lastname: Carella
authors.forename: G
authors.initials: G
authors.lastname: Beltrami
authors.forename: P R
authors.initials: PR
authors.lastname: Scalzulli
authors.forename: A M
authors.initials: AM
authors.lastname: Carella
authors.forename: M T
authors.initials: MT
authors.lastname: Corsetti
mesh_terms: D000208:Acute Disease; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013256:Steroids / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D013256:Steroids; D000074323:Alemtuzumab